The failure to set up a separate evaluation process for orphan drugs and the lack of opportunity for patient engagement when considering their reimbursement has been criticised by politicians from all parties.

Patients who suffer from a chronic lung condition, Alpha 1, were told last Friday that they will lose access to a vital drug called Respreeza at the end of the month.